ArticleArthritis research & therapy2017

Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.

Natalia V Giltiay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.